SK284258B6 - Použitie 1-ar(alk)ylimidazolín-2-ónu na výrobu liečiva na ošetrovanie stavov strachu a napätia - Google Patents
Použitie 1-ar(alk)ylimidazolín-2-ónu na výrobu liečiva na ošetrovanie stavov strachu a napätia Download PDFInfo
- Publication number
- SK284258B6 SK284258B6 SK1584-99A SK158499A SK284258B6 SK 284258 B6 SK284258 B6 SK 284258B6 SK 158499 A SK158499 A SK 158499A SK 284258 B6 SK284258 B6 SK 284258B6
- Authority
- SK
- Slovakia
- Prior art keywords
- formula
- fear
- group
- compound
- imidazolin
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract description 5
- 230000036506 anxiety Effects 0.000 title abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 29
- 229960003529 diazepam Drugs 0.000 claims description 12
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- ADOLLNOHUDQRCE-UHFFFAOYSA-N 1-(4-chlorophenyl)-4-morpholin-4-ylimidazolidin-2-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)NC(N2CCOCC2)C1 ADOLLNOHUDQRCE-UHFFFAOYSA-N 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229960003120 clonazepam Drugs 0.000 description 10
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 10
- 230000000949 anxiolytic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 229960002225 medazepam Drugs 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000029808 Psychomotor disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000013409 limited attention Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19721580A DE19721580A1 (de) | 1997-05-23 | 1997-05-23 | Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen |
| PCT/DE1998/001343 WO1998052548A2 (fr) | 1997-05-23 | 1998-05-14 | Utilisation de 1-ar(alk)yl-imidazolin-2-one pour le traitement de l'angoisse et du stress |
| US09/079,802 US5994347A (en) | 1997-05-23 | 1998-05-15 | For a process for treatment of anxiety and tension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK158499A3 SK158499A3 (en) | 2001-03-12 |
| SK284258B6 true SK284258B6 (sk) | 2004-12-01 |
Family
ID=26036759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1584-99A SK284258B6 (sk) | 1997-05-23 | 1998-05-14 | Použitie 1-ar(alk)ylimidazolín-2-ónu na výrobu liečiva na ošetrovanie stavov strachu a napätia |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5994347A (fr) |
| EP (1) | EP0979083B1 (fr) |
| JP (1) | JP4838403B2 (fr) |
| CN (1) | CN1150901C (fr) |
| AR (1) | AR012746A1 (fr) |
| AT (1) | ATE246926T1 (fr) |
| AU (1) | AU745536B2 (fr) |
| BG (1) | BG63378B1 (fr) |
| BR (1) | BR9809666A (fr) |
| CA (1) | CA2291075C (fr) |
| DE (2) | DE19721580A1 (fr) |
| DK (1) | DK0979083T3 (fr) |
| ES (1) | ES2205516T3 (fr) |
| HU (1) | HUP0003108A3 (fr) |
| IL (1) | IL132652A0 (fr) |
| NO (1) | NO325346B1 (fr) |
| NZ (1) | NZ500849A (fr) |
| PL (1) | PL193589B1 (fr) |
| PT (1) | PT979083E (fr) |
| RU (1) | RU2203055C2 (fr) |
| SK (1) | SK284258B6 (fr) |
| TR (1) | TR199902815T2 (fr) |
| TW (1) | TW579294B (fr) |
| WO (1) | WO1998052548A2 (fr) |
| ZA (1) | ZA984197B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL166593A0 (en) | 2002-08-02 | 2006-01-15 | Racemization and enantiomer separation of clopidogrel | |
| US20050070537A1 (en) | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
| CA2531861A1 (fr) * | 2003-07-11 | 2005-01-20 | Elbion Ag | Methode de traitement ou de prevention de troubles du systeme nerveux central au moyen de composes a selectivite pour la sous-unite alpha 3 du recepteur des benzodiazepines |
| US8097271B2 (en) | 2004-08-11 | 2012-01-17 | Kraft Foods Global Brands Llc | Warming compositions and delivery systems therefor |
| US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044021A (en) * | 1971-10-21 | 1977-08-23 | American Cyanamid Company | Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism |
| RU94027048A (ru) * | 1994-07-18 | 1996-05-20 | Иркутский институт органической химии СО РАН | Анксиолитическое средство |
| DE19532668A1 (de) * | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
| US5869481A (en) * | 1995-09-05 | 1999-02-09 | Arzneitmittelwerk Dresden G.M.B.H. | Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making |
-
1997
- 1997-05-23 DE DE19721580A patent/DE19721580A1/de not_active Withdrawn
-
1998
- 1998-05-14 CN CNB988053748A patent/CN1150901C/zh not_active Expired - Lifetime
- 1998-05-14 SK SK1584-99A patent/SK284258B6/sk not_active IP Right Cessation
- 1998-05-14 ES ES98933532T patent/ES2205516T3/es not_active Expired - Lifetime
- 1998-05-14 CA CA002291075A patent/CA2291075C/fr not_active Expired - Lifetime
- 1998-05-14 JP JP54979698A patent/JP4838403B2/ja not_active Expired - Lifetime
- 1998-05-14 PT PT98933532T patent/PT979083E/pt unknown
- 1998-05-14 DE DE59809285T patent/DE59809285D1/de not_active Expired - Lifetime
- 1998-05-14 BR BR9809666-4A patent/BR9809666A/pt not_active Application Discontinuation
- 1998-05-14 WO PCT/DE1998/001343 patent/WO1998052548A2/fr not_active Ceased
- 1998-05-14 NZ NZ500849A patent/NZ500849A/en unknown
- 1998-05-14 PL PL98337090A patent/PL193589B1/pl not_active IP Right Cessation
- 1998-05-14 HU HU0003108A patent/HUP0003108A3/hu unknown
- 1998-05-14 EP EP98933532A patent/EP0979083B1/fr not_active Expired - Lifetime
- 1998-05-14 IL IL13265298A patent/IL132652A0/xx not_active IP Right Cessation
- 1998-05-14 RU RU99128109/14A patent/RU2203055C2/ru active
- 1998-05-14 TR TR1999/02815T patent/TR199902815T2/xx unknown
- 1998-05-14 AT AT98933532T patent/ATE246926T1/de not_active IP Right Cessation
- 1998-05-14 DK DK98933532T patent/DK0979083T3/da active
- 1998-05-14 AU AU83326/98A patent/AU745536B2/en not_active Expired
- 1998-05-15 US US09/079,802 patent/US5994347A/en not_active Expired - Lifetime
- 1998-05-19 ZA ZA9804197A patent/ZA984197B/xx unknown
- 1998-05-20 TW TW087107848A patent/TW579294B/zh not_active IP Right Cessation
- 1998-05-22 AR ARP980102409A patent/AR012746A1/es not_active Application Discontinuation
-
1999
- 1999-10-29 NO NO19995300A patent/NO325346B1/no not_active IP Right Cessation
- 1999-11-04 BG BG103859A patent/BG63378B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krupitsky et al. | Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam | |
| USRE36397E (en) | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity | |
| EP2206498B9 (fr) | Agonistes mixtes des récepteurs ORL1/[mu] pour le traitement de la douleur | |
| Robbe et al. | Metabotropic glutamate receptor 2/3‐dependent long‐term depression in the nucleus accumbens is blocked in morphine withdrawn mice | |
| EP2340254B1 (fr) | Compositions et procédés pour traiter l épilepsie | |
| CA2761716A1 (fr) | Traitement de troubles cognitifs avec certains recepteurs nicotiniques de type alpha-7 a en combinaison avec des inhibiteurs de l'acetylcholinesterase | |
| Kesmati et al. | Magnesium oxide nanoparticles reduce anxiety induced by morphine withdrawal in adult male mice | |
| Zhou et al. | Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone | |
| Budzynska et al. | Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm | |
| SK284258B6 (sk) | Použitie 1-ar(alk)ylimidazolín-2-ónu na výrobu liečiva na ošetrovanie stavov strachu a napätia | |
| Borowicz et al. | Chronically administered fluoxetine enhances the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model | |
| Acuña et al. | Promising immunomodulators for management of substance and alcohol use disorders | |
| CZ9904182A3 (cs) | Užití 1-aralkylimidazolin 2-onu pro léčení stavů úzkosti a stresů | |
| Prus et al. | Acute nicotine reduces and repeated nicotine increases spontaneous activity in male and female Lewis rats | |
| KR100577626B1 (ko) | 1-아르(알크)일-이미다졸린-2-온을 포함하는, 불안 치료용 약제학적 조성물 | |
| Davoudi et al. | Effects of dietary nitrate or nitrite supplementation on inhibitory avoidance task and pentylenetetrazoleinduced clonic seizure threshold in mice. | |
| Rodríguez-Silverio et al. | Research Article Evaluation of the Antinociceptive Activity of Calein D and Exploration of the Possible Mechanism of Action | |
| Eshra et al. | Ketamine potentiates a central glutamatergic presynapse | |
| Battaglia et al. | A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia | |
| MXPA99010609A (en) | Use of 1-ar(alk)yl-imidazolin-2-one for treating anxiety and stress conditions | |
| SAYIN et al. | Gamma-vinyl-GABA potentiates the severity of naloxone-precipitated abstinence signs in morphine-dependent rats | |
| CZ2003234A3 (cs) | 2-Aryl-8-oxodihydropurinové deriváty jako léčivo | |
| RABANI et al. | Acute and chronic effects of nitrendipine on naloxone precipitated morphine withdrawal in mice | |
| Rathod et al. | Role of L-lysine in Ethanol Induced Behavioral Changes in Mice | |
| Hitomi et al. | Dose-dependent effects of repeated ketamine administration on muscarinic acetylcholine receptors in the mouse forebrain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20100514 |